Cristin Bruns, MD
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1053364224
Payments from drug & device makers
Across 426 payments — averaging $373.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$48K
- Novo Nordisk$35K
- AstraZeneca$24K
- Lilly USA, LLC$22K
- Abbott$21K
- AbbVie$6K
- plus $3K from 28 others
What the payments were for
- Consulting fees$8,4435%
- Speaking & faculty fees$139,38988%
- Travel & lodging$4,4973%
- Food & beverage$6,4464%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 93 | $48,396 |
| Novo Nordisk | 73 | $34,775 |
| AstraZeneca(2 entities) | 54 | $23,760 |
| Lilly USA, LLC | 65 | $21,675 |
| Abbott | 53 | $21,230 |
| AbbVie | 12 | $6,473 |
| Corcept Therapeutics | 3 | $907 |
| Medtronic | 6 | $343 |
| Tandem Diabetes Care, Inc. | 7 | $252 |
| Dexcom, Inc. | 13 | $226 |
| Esperion Therapeutics, Inc. | 2 | $140 |
| Insulet Corporation | 4 | $81 |
| Antares Pharma, Inc. | 5 | $73 |
| Amarin Pharma, Inc. | 4 | $73 |
| Novartis | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Amgen | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 1 | $38 |
| Radius Health, Inc. | 2 | $34 |
| Cequr Corporation | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Bayer | 1 | $18 |
| Nalpropion Pharmaceuticals LLC | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Sandoz | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Siemens Medical Solutions USA, Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$68,603
- FARXIGA$23,149
- Ozempic$10,535
- Tresiba$8,714
- FREESTYLE LIBRE 3$8,568
- RYBELSUS$8,129
- Synthroid$6,375
- FreeStyle Libre$5,186
- Victoza$5,096
- FreeStyle Libre Pro$3,706
- FreeStyle Libre 2$3,301
- Korlym$875
- SIMPLERA SENSOR$155
- NEXLIZET$125
- NEXLETOL$125
- t:slim X2 Insulin Pump with Control-IQ$119
- MINIMED 780G$118
How this compares
$158,924 in reported general payments places this provider in the 90th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $89,213 |
| JardianceEmpagliflozin | 81 | $49,065 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $46,873 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $23,941 |
| MounjaroTirzepatide | 21 | $23,565 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $17,553 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,167 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $5,998 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $4,706 |
| SynthroidLevothyroxine Sodium | 126 | $3,408 |
| Novolog FlexpenInsulin Aspart | 40 | $3,035 |
| Droplet Pen NeedlePen Needle, Diabetic | 32 | $1,582 |
| NovologInsulin Aspart | 11 | $1,385 |
| Novolin NInsulin Nph Human Isophane | 12 | $652 |
| Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 15 | $628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $34,775 | $90,597105 claims |
| Boehringer IngelheimJardiance | $48,396 | $49,06581 claims |
| Lilly USA, LLCMounjaro | $21,675 | $23,56521 claims |
| AbbVieSynthroid | $6,473 | $3,408126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Donald AspensonTulsa$153K
- Elie AbedTulsa$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Lauren LabryerTulsa$12K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.